It’s okay to feel BLUE: Beating expectations, bluebird bio ($BLUE) raised $101 million for a total valuation of $389 million. The Cambridge biotech is working on developing new gene therapies.
As Fierce Biotech notes, the successful outing comes as something of a thaw for investors wary of risky, capital-intensive life sciences bets.
“But since the beginning of the year there’s been a growing queue of biotechs lining up at the newly open IPO window, and bluebird’s news is bound to inspire more such offering,” wrote John Carroll.
Follow the Hive on Twitter for analysis of this and other area innovation news.